Though both glucocorticoid alterations and memory impairments have been noted in posttraumatic stress disorder (PTSD), it is not clear if these phenomena are causally linked. As there is emerging evidence that these domains become further altered in PTSD with increasing age, it is of interest to examine these relationships in an older cohort. Aging (mean age, 62.778.9; range, 52-81) combat veterans with (n ¼ 13) and without (n ¼ 17) PTSD received an intravenous bolus of 17.5 mg hydrocortisone (cortisol), a naturally occurring glucocorticoid, or placebo in a randomized, double-blind manner, on two mornings approximately 1-2 weeks apart. Neuropsychological testing to evaluate episodic and working memory performance was performed 75 min later. Cortisol enhanced episodic memory performance in both groups of subjects, but enhanced elements of working memory performance only in the PTSD + group. The preferential effect of cortisol administration on working memory in PTSD may be related to the superimposition of PTSD and age, as cortisol had impairing effects on this task in a previously studied, younger cohort. The findings suggest that there may be opportunities for developing therapeutic strategies using glucocorticoids in the treatment of aging combat veterans.
INTRODUCTION
Glucocorticoids affect cognitive performance (Sauro et al, 2003; Het et al, 2005) , and cognitive performance is often compromised in psychiatric disorders characterized by glucocorticoid alterations (Wolkowitz et al, 1990; Belanoff et al, 2001; Vythilingam et al, 2004) . To the extent that memory problems are causally linked with glucocorticoid alterations, it might be possible to enhance cognitive performance using interventions that target glucocorticoid activity in brain.
In posttraumatic stress disorder (PTSD), both glucocorticoid alterations and impairments in memory performance have been demonstrated. A major glucocorticoid alteration in PTSD appears to be an increased responsiveness to glucocorticoids, evidenced by an enhanced sensitivity of Type II glucocorticoid receptors to in vivo and in vitro glucocorticoid challenge, that is often accompanied by reduced cortisol levels (Yehuda et al, 2004a, b; Rohleder et al, 2004; Yehuda, 2002) . These neuroendocrine alterations in PTSD differ from those observed in major depression and normal aging, conditions that have been associated with reduced glucocorticoid responsiveness and increased cortisol levels (O'Brien et al, 1999; Sapolsky 2000; Lupien et al, 1999; Yehuda et al, 1996) . The major cognitive decrements described in PTSD have involved performance on tests of episodic memory (Vasterling et al, 2002; Veltmeyer et al, 2005; Bremner et al, 1995; Yehuda et al, 1995) . These deficits have implicated medial temporal circuits, particularly, the hippocampus, a region that has been shown to be responsive to glucocorticoids, involved in episodic memory, and manifesting structural and functional alterations in PTSD (Mirescu and Gould, 2006; Sauro et al, 2003; Het et al, 2005; Kitayama et al, 2005) .
However, emerging evidence demonstrates that biologic alterations in PTSD are not necessarily static, and do appear to change with age. Memory impairments in PTSD appear to become more prominent with aging (Yehuda et al, 2005a) . Compared to older veterans without PTSD, older combat veterans with PTSD show a greater decrement in aspects of memory that were demonstrated to be impaired in younger veterans with PTSD. Moreover, older veterans with PTSD also demonstrated a greater range of alterations in memory domains previously found to be unaffected, such as in immediate recall, acquisition of memory, cumulative learning, and active interference from previous learning compared to older veterans without PTSD. With respect to glucocorticoid alterations, cross-sectional and longitudinal studies demonstrated an even greater diminution in ambient cortisol levels over time in trauma survivors, a finding that is in the opposite direction of the progressive increases in cortisol described in aging (Yehuda et al, 2006c; Yehuda et al, in press ). In contrast, older trauma survivors also showed a flattening of the circadian rhythm of cortisol, which is similar to what has been described in normal aging (Yehuda et al, in preparation; Yehuda et al, 2005b) , suggesting a superimposition of aging with PTSD effects in older trauma survivors. In contrast, it does not appear that hippocampal volume in PTSD continues to decrease over time. Though the smaller hippocampal volume present in younger subjects with PTSD is similar to atrophy associated with normal aging processes, the failure of three published studies to detect group difference in elderly trauma survivors suggests that this biologic alteration may no longer be evident at a time when healthy subjects are not manifesting normal age-related atrophy in this region (Freeman et al, 2006; Yehuda et al, 2006a; Golier et al, 2005) . These findings raise the question whether the increased cognitive decline in aging trauma survivors with PTSD is mediated by the same biologic mechanisms, eg hippocampal atrophy induced by age-related increases in glucocorticoid release (Sapolsky, 2000; Miller and O'Callaghan, 2005; Lupien et al, 2005; Golomb et al, 1996) .
We recently reported that in younger subjects with PTSD, cortisol administration impaired performance on working memory (Grossman et al, 2006) . These findings are consistent with the literature on the effects of cortisol administration in healthy volunteers, which has most often demonstrated impairing effects of cortisol on memory performance (see, for review, Sauro et al, 2003; Het et al, 2005 ). Yet, in predicting the effects of cortisol administration in older subjects, it is tempting to posit that opposite effects would be observed. Indeed, although an argument can be made that increased glucocorticoid sensitivity would result in an amplification of cortisol's negative effects, it might also be the case that as cortisol levels fail to increase in PTSD in aging persons, there is some protection from damaging effects of age-related hippocampal atrophy and memory decline.
In considering specific predictions with respect to glucocorticoid effects in any individual or cohort, there are many factors, including dose and timing of glucocorticoid administration, type of memory process being measured, and individual differences relating to clinical status and age that can affect this relationship (Roozendaal, 2002) . With respect to dosing, higher doses of cortisol (eg 160 mg/day using split doses to approximate circadian rhythm) were found to be generally more impairing than lower doses (eg 40 mg/day), and doses that resulted in moderate levels of cortisol (eg 50 mg/day) were more beneficial than those resulting in levels that are too low (eg 25 mg/day) (Newcomer et al, 1999) . In terms of timing, glucocorticoids are more beneficial when administered in the evening, when cortisol levels are naturally lower in the diurnal cycle than in the morning when they are naturally elevated (Lupien and Lepage, 2001; Lupien et al, 2002) . Regarding memory processes, cortisol impairs performance when administered during memory retrieval but not if administered before learning (Het et al, 2005) , and is more likely to affect adversely the recall of previously learned information but enhance learning of new information . Cortisol also appears to impair memory for emotionally arousing material (Rimmele et al, 2003) , but to be beneficial with respect to memory for neutral stimuli (Buchanan and Lovallo, 2001) .
Despite the importance of these other factors, differences in clinical status and aging may be specifically relevant with respect to predictions of cortisol effects in aging subjects with PTSD. For example, the synthetic hormone, dexamethasone, has been shown to have a beneficial effect on memory performance in depression (Bremner et al, 2004a) , but a deleterious effect on healthy volunteers, and no effect in younger subjects with PTSD (Bremner et al, 2004b) . Dexamethasone acts primarily at the pituitary and results in a drastic reduction of endogenous cortisol, supporting the idea that memory effects are strongly influenced by ambient cortisol levels. To the extent that these findings are explained by respective differences in ambient cortisol levels associated with these clinical states, this would support the idea that cortisol effects on memory depend on ambient hormone levels. Changes in ambient cortisol levels associated with aging might also explain the differential effects of glucocorticoids associated with aging. For example, in contrast to effects typically observed in younger subjects, a study of normal elderly subjects showed no significant adverse effects of cortisol on a range of cognitive functions (Porter et al, 2002) . Furthermore, in elderly subjects with a 5-year history of moderate cortisol levels, metyrapone treatment, which acutely decreases cortisol, significantly impaired memory performance, whereas in elderly subjects with a 5-year history of high cortisol levels, cortisol administration treatment significantly decreased delayed memory . Stress-induced cortisol elevations also decreased delayed memory (Elzinga et al, 2005) . Thus, there is evidence for an 'optimal level' of glucocorticoid functioning, deflections from which in either the lower or higher direction have predictable adverse effects on aspects of memory functioning.
This brief review highlights that glucocorticoid effects on memory function are multidetermined, but that one of the critical factors may certainly be ambient cortisol concentration, which in PTSD is often normal or even lower than normal, despite evidence for corticototropin-releasing hormone (CRH) hypersecretion (Yehuda, 2002) . Accordingly, we hypothesized that glucocorticoid administration could be more beneficial in PTSD than in comparison subjects, particularly if administered at a low to moderate dose before learning new, neutral information.
To test this hypothesis, we utilized a randomized, doubleblind, crossover design in which we administered both an intravenous (i.v.) bolus of 17.5 mg hydrocortisone succinate, a naturally occurring glucocorticoid, and placebo to aging combat veterans with and without PTSD. When administered as an i.v. bolus, this dose achieves plasma cortisol elevations that are high, but well within the physiologic range (Yehuda et al, 2006b) . We examined several different aspects of memory performance, including both episodic and working memory, and related differences in performance to the biological activity of cortisol, indexed by suppression of adrenocorticotropin hormone (ACTH).
METHODS

Participants
Thirty male veterans aged 52-81 years provided written informed consent to participate. The study was approved by the Institutional Review Boards of Mount Sinai School of Medicine, and of the Bronx Veterans Affairs.
Subjects were included in the PTSD group if they met the diagnostic criteria for current PTSD and were included in the PTSDÀ group if they were free from a current or past history of PTSD or major Axis I disorder. Subjects with PTSD were excluded if they had comorbid substance dependence, bipolar disorder, or psychosis, but not if they were suffering from current major depression or dysthymia or another anxiety disorder. Participants did not have any major medical, endocrinological, or neurological illness or head injury based on physical examination with laboratory tests, and were not taking antidepressants or other psychotropic medications.
Clinical Assessments
Information about traumatic life events was obtained using the Trauma History Questionnaire (Green, 1995) . Subjects who endorsed a 'Criterion A' event, which, for the majority, included a combat or another military-related experience, were evaluated with the clinician administered PTSD scale (CAPS) (Blake et al, 1995) . Other Axis I diagnoses were made using the structured clinical interview for DSM-IV (Spitzer et al, 1995) . Diagnostic interviews were conducted by one of three licensed clinical psychologists with established interrater reliability. All diagnoses were reviewed at consensus conference by a team of psychologists and psychiatrists who were unaware of the biologic data.
Neuroendocrine Testing and Biological Measures
Cortisol challenge test. On two separate occasions, within 1-2 weeks apart, each participant received 17.5 mg cortisol (hydrocortisone sodium succinate (Solucortef)) or placebo administered by a physician. To control for order effects, the occurrence of drug and placebo occurred randomly in each of the two groups on the first session and was then counterbalanced in each group separately by alternating between placebo and cortisol day.
Subjects were instructed to eat a light breakfast at 0600 and report to the laboratory by 0800. A special sideperforated 20-gauge catheter with a stopcock for venous blood sampling was placed in the antecubital region, and a second catheter (24 gauge) placed in the contralateral antecubital region for delivery of cortisol or placebo. The catheter was kept patent with a slow saline drip. A baseline sample was collected 10 min before the injection of a bolus of saline or cortisol. Samples were obtained at several intervals postinjection for ACTH and cortisol determination (data presented elsewhere), and the generally lowest ACTH value (at 90 min postinjection) was used as a reflection of the neuroendocrine response to cortisol.
Neuroendocrine procedures and laboratory assays. Plasma ACTH levels were determined by radioimmunoassay using the ACTH IRMA kit from Nichols Institute Diagnostics (San Juan Capistrano, CA). The detection limit was 0.02 ng/ml. The intra-and inter-assay variability was 4.7 and 7.1%, respectively.
To obtain a more informative measure of ambient cortisol than can be achieved with a baseline estimate on a test day, we asked subjects, several days before the testing procedure, to collect salivary samples at home at wake-up, at 30 and 60 min postawakening, and bedtime. Salivary cortisol levels were analyzed as described previously (Goenjian et al, 1996) .
Neuropsychological Testing
We measured memory performance with a battery lasting approximately 30 min, beginning at 75 min postinjection, after subjects had received a positron emission tomography scan (data presented elsewhere). The neuropsychiatric examination was designed to assess explicit and working memory tasks that have been previously demonstrated to be vulnerable to glucocorticoid administration (Kirschbaum et al, 1996; Newcomer et al, 1994; Wolkowitz et al, 1990) . Episodic memory (verbal learning), as measured by immediate and delayed paragraph recall (ie Logical Memory from the Wechsler Memory Scale (third edition, WMS-III)) (Wechsler, 1997) was used. To minimize practice effects, two different paragraphs were administered in random order across conditions. Attention and maintenance working memory was assessed using the Digit Span Forward (DSF) subtest of the WMS-III. Manipulation working memory was measured by the Digit Span Backwards (DSB), and the letter number sequencing (LNS) subtests of the WMS-III. For the Digit Span and LNS subtests, only one version is available and was used on both test days.
Data Analysis
Group differences in baseline cortisol levels were evaluated using repeated measures analysis of variance (ANOVA) of wake-up, wake-up + 30, wake up + 60, and bedtime cortisol. Analysis of the response to cortisol proceeded in several steps. As each subject was tested twice, once on placebo and once on cortisol, the random assignment to a drug order was confounded with the interaction of drug by injection order. Preliminary repeated measures ANOVA were performed for each of the six dependent variables assessing effects of session (first, second), drug (placebo, cortisol) and their interaction, which was the injection order group (placebo first, cortisol first). For each dependent variable separately, the primary analysis was a comparison of the performance of two groups (PTSD + , PTSDÀ) on the two drugs. For each dependent variable separately, session and/or injection order were used as covariates when they were significant in the preliminary repeated measures analyses. This controlled for substantial session or injection order effects, without complicating the analyses by the inclusion of less relevant covariates. Other potential covariates, such as presence or absence of comorbid depression and anxiety were also examined and were not found to impact the data significantly. Effect sizes for the groups' drug vs placebo differences were calculated using Cohen's d, effect sizes for differences between groups were evaluated using Z 2 (Cohen, 1988) . Correlational analyses were used to determine the relationships between the extent to which memory performance was altered in response to cortisol (expressed as the difference between performance following cortisol minus performance on the placebo day) and the ACTH levels at 90 min following cortisol (ie corresponding to the time where ACTH levels are maximally suppressed) expressed as the natural logarithm.
RESULTS
Characteristics of the Sample
Demographic and clinical characteristics of the sample, and results of statistical analyses of these variables, are reported in Table 1 . Participants in the groups with and without PTSD were comparable in age and ethnic distribution. The groups differed with respect to the proportion of veterans who experienced combat trauma, but did not differ in age at focal trauma. The PTSD + group showed greater symptom severity in the intrusive, avoidance and hyperarousal subscales of the CAPS, and on total Mississippi PTSD Scale scores. Of the 13 participants with current PTSD, four had a comorbid diagnosis of major depressive disorder and seven had a diagnosis of another anxiety disorder. Table 1 also shows a trend-level main effect of Group (p ¼ 0.055), reflecting generally lower cortisol levels in the PTSD + at Table 2 presents the results of the preliminary repeated measures analyses identifying the session and injection order variables to be controlled in the primary repeated measures analyses of group differences in the effects of cortisol on memory performance. The only measures in which there was a significant or trend-level order effect were the two subtests of the Digit Span test. For these two measures, and also for LNS, there was a significant effect of Injection Order, which suggested improved performance on the second assessment when cortisol was administered on the first test day. Accordingly, for analyses of these measures Injection Order was included as a covariate.
Effects of Potential Effects of Injection Order
Effect of Cortisol on Memory Performance
There was a significant main effect of Group on retention (indexed by percent savings at delay on the Logical Memory Scale (LMS)), reflecting a significant decrement in the PTSD + compared to the PTSDÀ group (F 1,28 ¼ 6.56, p ¼ 0.016). This decrement was observed under both the placebo and cortisol conditions. Subjects without PTSD retained 95.8% of immediately acquired information following delay under placebo conditions, whereas those in the PTSD + group retained 89.2%. The PTSDÀ group retained 85.2% on the cortisol day, compared to 94.1 % in the PTSD + group. There was no main effect of Drug (F 1,28 ¼ 1.42, NS) and no Group Â Drug interaction (F 1,28 ¼ 0.21, NS). When the two components of this test, Immediate and Delayed recall, were analyzed as repeated measures, so that each subject had four observations (placebo and cortisol for each subtest), there was a significant main effect of Drug (F 1,28 ¼ 8.9, p ¼ 0.006) with overall memory performance in both groups better on cortisol, as well as a main effect of Subtest (F 1,28 ¼ 35.07, po0.0001), indicating that participants in both groups scored lower in the delayed condition. As graphed in Figure 1 , there was also a Group Â Subtest interaction (F 1,28 ¼ 6.56, p ¼ 0.016), demonstrating that performance in the delayed recall condition was worse for subjects in the PTSD + group. The absence of a Drug Â Subtest interaction (F 1,28 ¼ 1.42, NS) indicated that, as expected, the effects of cortisol on each subtest were similar; indeed cortisol resulted in an increase of 18.6% in immediate recall and 18.4% in delayed recall when both groups were considered together.
Results for the DSF and DSB tests are graphed in Figure 2 . For the DSF subtest, reflecting attention and maintenance working memory, repeated measures analysis of covariance (ANCOVA) demonstrated a main effect of Drug (F 1,27 ¼ 11.68, p ¼ 0.002). Here too, after controlling for Injection Order, there was no Group Â Drug interaction (F 1,27 ¼ 2.33, p ¼ 0.14), and only a trend for a main effect of Group (F 1,27 ¼ 3.07, p ¼ 0.09). There was a main effect of the covariate of Injection Order (F 1,27 ¼ 6.10, p ¼ 0.02) and a Drug Â Injection Order (F 1,27 ¼ 9.86, p ¼ 0.004) interaction. As it is inappropriate to use ANCOVA when there is a strong interaction between the covariate and an independent variable, to better distinguish injection order effects across drug conditions, data from the cortisol and placebo days were analyzed separately with two-way univariate ANOVAs, using Group and Injection Order as main effects. On the placebo day for DSF, ANOVA revealed significant main effects of Group (F 1,29 ¼ 4.27, p ¼ 0.049) and Injection Order (F 1,29 ¼ 10.42, p ¼ 0.003), but no Group Â Injection Order interaction (F 1,29 ¼ 0.002, NS). In contrast, analysis of DSF scores on the cortisol day indicated no main effect of Order are presented as a preliminary analysis to identify variables that must be controlled for when performing the primary analysis concerning drug and group effects. In the absence of an effect of Injection Order, a main effect of Session would constitute a practice effect. Similarly, in the absence of a main effect of Session, a main effect of Injection Order indicates an effect of drug that is independent from a practice effect. The results of these analyses demonstrate that for the Digit Span Total variables, it was necessary to control for Session and Injection Order. For the LNS, no practice effects were observed per se, but the main effect of Injection Order indicated that it was necessary to control for this variable in the analyses comparing the two groups.
Group (F 1,29 ¼ 1.31, NS) or Injection Order (F 1,29 ¼ 1.09, NS), and no Group Â Injection Order interaction (F 1,29 ¼ 1.21, NS). These results reflect that on the placebo day, the PTSD + group performed significantly worse than the PTSDÀ group regardless of injection order (mean7SD: 8.6973.51, 10.8272.30 for PTSD + , PTSDÀ, respectively). However, the effect of injection order was to enhance performance in both groups on the placebo day when that assessment was preceded by cortisol administration (mean7SD: 10.3373.14, 12.2271.79 for PTSD + and PTSDÀ, respectively) compared to when it was administered first (mean7SD: 7.973.40, 9.2571.75 for the PTSD + and PTSDÀ, respectively). The lack of a comparable enhanced performance when cortisol was administered on the second test day indicates that the improvement related to cortisol was not simply a practice effect, but rather that cortisol injection lead to a carryover effect of enhanced working memory performance (ie enhanced practice effect). For DSB, reflecting manipulation as well as maintenance working memory demands, there was a nonsignificant trend for a main effect of Drug (F 1,27 ¼ 3.87, p ¼ 0.06), no Drug Â Group interaction (F 1,27 ¼ 2.30, NS) and no effect of Group (F 1,27 ¼ 1.11, NS). The covariate of Injection Order was significant (F 1,27 ¼ 8.86, p ¼ 0.006), again reflecting better performance in both groups when cortisol was administered on the first day. There was no interaction between Injection Order and Drug.
For LNS, a different pattern was observed, also graphed in Figure 2 . Here, repeated measures ANCOVA demonstrated a significant Group Â Drug interaction (F 1,27 ¼ 4.98, p ¼ 0.034) in the absence of a main effect of Drug (F 1,27 ¼ 0.98, NS) or Group (F 1,27 ¼ 1.15, NS). The interaction demonstrated that although subjects in the PTSD + group started out performing more poorly than those in the PTSDÀ group on this relatively difficult task, cortisol injection significantly improved their performance although having no effect in subjects in the PTSDÀ group. A main effect of Injection Order (F 1,27 ¼ 7.99, p ¼ 0.009) was observed reflecting a higher performance in both groups if cortisol was administered before placebo. Here too, there was no interaction between Injection Order and Drug.
To examine whether the memory effects observed were moderated by ambient cortisol levels, we repeated the above analyses using the maximum cortisol level achieved following cortisol administration as a covariate. This reduced to a trend, but did not obliterate, the Group Â Drug effect (F 1,24 ¼ 3.90, p ¼ 0.06). However, there was a clearly significant effect of the covariate (F 1,24 ¼ 5.18, p ¼ 0.032). When the analysis was repeated using the minimum ACTH Data for the PTSDÀ and PTSD + groups are depicted by & and K, respectively. On DSF, the mean7standard error of the mean for PTSDÀ (n ¼ 17) and PTSD + (n ¼ 13) groups on the placebo day was 10.770.6 and 8.870.7, respectively, and 10.770.6 and 9.770.6 on the day of cortisol administration. On DSB, the mean7standard error for PTSDÀ and PTSD + groups on placebo day was 8.170.6 and 6.770.7, and 7.870.6 and 7.470.7 on the day of cortisol administration. On LNS, the mean7standard error for PTSDÀ and PTSD + groups on placebo day was 9.570.6 and 7.870.7, and 9.570.8 and 9.270.8 on the day of cortisol administration.
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response on the cortisol day as a covariate, this too had a small effect on the Group Â Drug interaction (F 1,24 ¼ 4.01, p ¼ 0.056), but ACTH levels were not found to be a significant covariate (F 1,24 ¼ 0.65, NS). In both analyses, there was no interaction between Group and the neuroendocrine covariate. These analyses suggest that ambient cortisol levels are generally related to working memory performance, comparably in both groups of subjects, but that the ACTH levels following cortisol, which likely represent an index of responsiveness to the cortisol challenge, may not be associated with performance on this type of task.
To provide a summary of the differences across tests and diagnostic groups in the effects of cortisol, the drug vs placebo effect sizes for the PTSD + and PTSDÀ samples graphed as Cohen's d, and effect sizes for PTSD + vs PTSDÀ comparisons expressed as Z 2 , are presented in Figure 3 . These findings show that the difference between drug and placebo on immediate and delayed recall was in the medium range for both subject groups. Similarly, the effects of cortisol on the working memory variables in the PTSD + samples were also in the medium range, whereas the effect sizes for the PTSDÀ group were negligible.
Relationships between changes in memory performance and an endocrine response to cortisol. In view of the apparent difference in the effects of cortisol on different aspects of memory performance across the two subject samples, we attempted to establish the biological validity of the cortisol challenge procedure. We present two scatterplots that depict the most divergent contrast in the effects of cortisol on episodic and working memories. There was a significant correlation between change in immediate recall and ACTH following cortisol administration (r ¼ À0.458, df ¼ 25, p ¼ 0.016; Figure 4 , panel a). It is clear that both groups had a similar response to cortisol administration from the similar slopes in the two groups (for PTSD + r ¼ À0.48; PTSDÀ r ¼ À0.43). For descriptive purposes, a similar scatterplot for change scores on LNS, the only test with a significant Group Â Drug interaction, is presented in Figure 4 , panel b. The scatterplot clearly suggests that there is no relationship between the ACTH response and change in LNS in the PTSDÀ or PTSD + groups (for PTSD + r ¼ À0.17; PTSDÀ r ¼ À0.014).
DISCUSSION
The main finding of this study is that an i.v. bolus of 17.5 mg cortisol enhanced episodic memory performance in both groups, but on a test that involves both maintenance and manipulation of working memory, cortisol only had beneficial effects in the PTSD + group. That the effect of cortisol in this older sample was generally to improve memory performance is evidenced by the significant main effects of drug observed on the immediate and delayed recall on the LMS and the trend-level effect of cortisol for attention as measured by DSF. But with respect to the LNS, the Group Â Drug interaction occurred in the absence of a main effect of Drug or Group, suggesting that although subjects in the PTSD + group started out performing more poorly than controls on this relatively difficult task, cortisol injection significantly improved their performance although having no effect in the controls. Significant effects of cortisol were not seen in relation to the Digit Span Total test, after controlling for injection order. It is somewhat surprising that subjects with PTSD showed a preferential response on the LNS than the Digit Span Total as both tasks purported to measure working memory. In evaluating this discrepancy, it should be kept in mind that these results may have a component of 'task specificity', as observed both by the absence of a practice effect on the LNS, and a relatively more impaired performance at baseline on the Digit Span Total in the PTSD + group. These factors, together, may have resulted in a slightly different response to cortisol administration and this issue does require further investigation. Also of importance is the fact that DSB performance was the task that was most strongly affected by cortisol in the PTSD + group (Figure 3) , with the lack of difference between PTSD + and PTSDÀ groups likely being nonsignificant because of low power alone.
As the PTSD + group performed more poorly than the PTSDÀ group on nearly every measure at baseline, the improvement with cortisol may partially reflect poor performance at the outset. With respect to episodic memory, both groups of veterans scored well below the maximum possible score, which may account for why both groups improved on this measure. However, the differential effects of cortisol in PTSD on a measure of working memory cannot be attributed exclusively to lower baseline memory performance in PTSD. This is because there was also a beneficial effect of receiving cortisol before placebo as evidenced by their higher Digit Span and LNS scores on the placebo day if they had first received cortisol. As the order of administration for cortisol vs placebo was randomized across subjects, these findings are best interpreted as representing a benefit of cortisol, rather than a practice effect. Although it could be argued that the cortisol effect in the PTSD group is confounded with the repetition of these tests, there did not appear to be a practice effect in either the PTSD + or PTSDÀ group. Arguably, subjects in the PTSDÀ group could have also shown some cortisol-induced imprinting, but that they did not further support the specificity of the response to cortisol in the PTSD group in this test.
The Group Â Drug interaction observed in this older cohort represents an effect of glucocorticoids that is opposite to what we observed previously in a cohort approximately 30 years younger, in which there was also a significant Group Â Drug interaction reflecting a decline in performance following cortisol in PTSD and no effect in controls (Grossman et al, 2006) . In that study, PTSD + subjects did not start out performing more poorly than participants without PTSD on working memory. That older subjects with PTSD show a greater deficit at baseline on working memory may reflect effects accruing from the constellation of biologic alterations in PTSD over time, or an accelerated age-related process. Accordingly, the beneficial effects of low-dose glucocorticoids may not be moderated by PTSD directly, but only become more pronounced in PTSD to the extent that the pattern of cortisol-related benefits of memory vary based on endocrine status or other individual differences of the subject.
A major limitation of the current study is the small sample sizes. However, estimated effect sizes for the statistically significant results were in the moderate to large range. Accordingly, it is unlikely that the lack of beneficial effects of cortisol on working memory in subjects without PTSD can be attributed to low power. In fact, the effects for subjects without PTSD were close to zero and would have only been detectible with an implausibly large sample size. Rather, the findings suggest that cortisol has differential effects on different aspects of memory as a function of clinical or neuroendocrine status of subjects. Indeed, the observation that ambient cortisol levels following cortisol administration were found to be a significant covariate in the analysis of the LNS data supports the conclusion that the beneficial effects of cortisol on memory performance in PTSD may be at least partially linked to correcting the lower levels of basal glucocorticoids. On the other hand, as neither the addition of ambient cortisol or the ACTH response to challenge obliterated the Group Â Drug interaction, but only reduced it somewhat, it may be that the differential effects of cortisol administration on memory are mediated by the actions of other neuropeptides, such as CRH or arginine-vasopressin (AVP), which are directly affected by glucocorticoid regulation, or other neurotransmitters such as norepinephrine or dopamine which have been shown to be altered in PTSD (O'Donnell et al, 2004; Glover et al, 2003; Segman et al, 2002; Yehuda et al, 1998) . Effects of cortisol on dopamine may be particularly relevant, as dopamine receptors have been demonstrated to be involved in working memory (Sawaguchi and Goldman-Rakic, 1991) . Furthermore, both animal and human studies have recently confirmed direct relationships between manipulations that increase or decrease glucocorticoid release and brain dopamine release (Pruessner et al, 2004; Pacak et al, 2002; Rouge-Pont et al, 1998) .
Interestingly, the results of the above-mentioned ANCOVA demonstrated that the relationship between cortisol and memory performance did not differ in the PTSD + and PTSDÀ groups. Thus, although the groups differed in the effect of cortisol on memory, this most likely reflects a group difference in ambient glucocorticoid levels or glucocorticoid receptor responsiveness. Indeed, in many respects, cortisol administration had comparable effects in the two groups. For example, cortisol administration not only improved episodic memory in both the PTSD + and PTSDÀ groups, but these improvements were similarly associated with responsiveness to cortisol as reflected by the log of the minimum ACTH level (ie reflecting maximum negative feedback effects of cortisol).
We have previously reported that subjects in this study showed an exaggerated suppression of ACTH in response to this dose of cortisol (Yehuda et al, 2006b) . However, for the PTSD + group, the physiological dose of cortisol administration improved memory performance to the point where they were no longer performing significantly less well than subjects in the PTSDÀ group. However, with respect to performance on the Digit Span Total and LNS, the improved performance after cortisol administration did not leave PTSD patients performing, as well as the healthy controls at baseline, even though it offered virtually no advantage to subjects in the PTSDÀ group. One explanation for this apparent discrepancy is that alterations in episodic memory may be state-related (Yehuda et al, 2006c) , and therefore constitute less stable consequences of enduring biological alterations.
The differential effects of cortisol in the PTSD + and PTSDÀ groups in working memory may implicate brain structures and circuitry outside the medial-temporal regions, such as in the anterior frontal lobe, as relevant to PTSD pathophysiology, and might also suggest an increasing role for these structures in PTSD with age. As recent studies demonstrate a particular role for both the dorsolateral prefrontal cortex and superior parietal cortex in tasks requiring the manipulation of working memory (Crone et al, 2006; Narayanana et al, 2005; Rypma and D'Esposito, 2003; Wager and Smith, 2003) particularly in aging subjects (Jennings et al, 2006; Kwee and Nakada, 2003; MacPherson et al, 2002; Rypma et al, 2001; Hazlett et al, 1998) , these regions should be examined in aging subjects with PTSD. Glucocorticoid-induced impairments in memory performance, particularly declarative and episodic memory, have also been associated with reduced blood flow in the medial temporal lobe (de Quervain et al, 2003) . However, insofar as PTSD + subjects showed enhanced suppression to ACTH on this challenge (Yehuda et al, 2006b) , it may be that the preferential effect to cortisol administration on working memory reflects increased glucocorticiod sensitivity in the anterior frontal lobe region, a region recently found to be sensitive to the effects of a single dose of cortisol in healthy volunteers in at least two separate reports (Hsu et al, 2003; Monk and Nelson, 2002) . Indeed, although glucocorticoid receptors are well known for their presence in the hippocampus, they are also present in the frontal cortex (Meaney and Aitken, 1985; Diorio et al, 1993; Watzka et al, 2000) , and may be preferentially sensitive in PTSD.
Finally, the findings may have treatment implications. Although the beneficial effects of glucocorticoids on memory performance has not been uniformly observed across studies of nonpsychiatric subjects, and even in younger subjects with PTSD, their ameliorative effects in the current study are consistent with current pharmacologic strategies aimed at targeting PTSD symptoms. Specifically, glucocorticoid administration has been shown to prevent the development of traumatic memories when administered prophylactically in the immediate aftermath of trauma exposure (Schelling et al, 2001 (Schelling et al, , 2004a , and also to decrease the intensity of intrusive memories when administered to persons with chronic PTSD (Aerni et al, 2004) . Importantly, these effects have been attributed to the impairing effects of cortisol on emotional memory retrieval, and not the enhancing effects of glucocorticoids on memory per se. This distinction is noteworthy as the glucocorticoid effects on emotional memories, compared to neutral ones, may not be affected by aging (Golier et al, 2002 (Golier et al, , 2003 . Regardless, insofar as glucocorticoid levels in the immediate aftermath and chronic PTSD have been reported as lower, the findings in aggregate offer proof of principle for the rationality of pursuing glucocorticoid-related treatment strategies in PTSD. Accordingly, it would be critical to examine neural correlates of cortisol administration in PTSD at baseline, in response to cognitive challenges, and to treatment. The current findings underscore the fact that it is not advisable to extrapolate from normal studies of aging that cortisol toxicity results in PTSD-related cognitive deficits. Doing so may result in a missed opportunity to exploit the potentially beneficial effects of cortisol on cognition and possibly symptom reduction in PTSD.
